Canada Could Come to the Fore in Cannabis Research

The coming legalization of recreational marijuana is already increasing funding for studies, but regulations on such research have been slow to change.

Written byAshley Yeager
| 4 min read
Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

On October 20, marijuana will no longer be an illegal drug in Canada—a move that could make it much easier to study how cannabis affects the body and the brain.

“Cannabis has risks and maybe benefits,” says M-J Milloy, an infectious disease epidemiologist at the British Columbia Centre on Substance Use and the University of British Columbia who studies HIV patients’ illicit drug use. Under prohibition, however, “what we, as scientists, have not been able to do is try to figure out what those risks and benefits are in an open way,” he says. “The hope is that legalization of cannabis will take the shackles off scientific inquiry and will allow us to ask and answer the sort of questions we should have been asking twenty, thirty, forty years ago.”

Currently in Canada, to study the physiological effects of cannabis in humans, researchers have to apply for an exemption from ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Ashley started at The Scientist in 2018. Before joining the staff, she worked as a freelance editor and writer, a writer at the Simons Foundation, and a web producer at Science News, among other positions. She holds a bachelor’s degree in journalism from the University of Tennessee, Knoxville, and a master’s degree in science writing from MIT. Ashley edits the Scientist to Watch and Profile sections of the magazine and writes news, features, and other stories for both online and print.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies